EQRx (EQRX) Stock Price, News & Analysis

Company Overview

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.

Key Stats

• Today's Range: $2.34 to $2.34
• 50-Day Range: $2.04 to $2.47
• 52-Week Range: $1.58 to $5.55
• Volume: N/A
• Average Volume: 3.30 million shs
• Market Capitalization: $1.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EQRX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of EQRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that EQRx investors own include Meta Platforms (META), NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Exxon Mobil (XOM), CrowdStrike (CRWD) and GE Aerospace (GE).

Company Calendar

• Today: 9/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EQRX
• CIK: 1843762
• Web: iii.cmlifesciencesspac.com
• Phone: 617-315-2255
• Fax: N/A
• Employees: 362
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$169.09 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.33%
• Return on Assets: -19.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.77
• Quick Ratio: 22.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.40 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 487,420,000
• Free Float: 398,218,000
• Market Cap: $1.14 billion
• Optionable: Optionable
• Beta: 0.48